Pseudomonas aeruginosa Colonization and COPD: The Chicken or the Egg?

Kunadharaju, Rajesh; Rudraraju, Avantika; Sethi, Sanjay

doi:10.1016/j.arbres.2021.12.001

Cited by 10 publications

(6 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A study conducted in Hong Kong on 1066 patients with non-cystic fibrosis bronchiectasis showed that in 27% of cases, P. aeruginosa was a colonizer, but nevertheless, the colonization was associated with a worse prognosis [36]. Other studies also present the importance of the respiratory tract colonization Kunadharaju et al showed that from more than 22,000 patients with chronic obstructive pulmonary disease, 4.2% presented repeated P. aeruginosa isolation from sputum for as long as 36 months [37]. In our results, the number of P. aeruginosa strains isolated during the pandemic situation, especially from the dermatology department (the main source in our situation), dropped down from n = 361 (12.31%) in 2019 to n = 81 (10.14%) in 2020; a high number of patients "disappeared" in 2020, due to COVID-19 restrictions.…”

Section: Discussionmentioning

confidence: 99%

Epidemiology, Evolution of Antimicrobial Profile and Genomic Fingerprints of Pseudomonas aeruginosa before and during COVID-19: Transition from Resistance to Susceptibility

Coșeriu

Vintilă

Mare

et al. 2022

Life

View full text Add to dashboard Cite

Background: The purpose of the study was to describe the epidemiological implication of Pseudomonas aeruginosa between 2017–2022 in a tertiary hospital from Romania, including the molecular fingerprinting of similar phenotypic strains (multidrug-resistant isolates), which would have an important health impact. The study also describes the resistance profile of P. aeruginosa before and during COVID-19, which might bring new information regarding the management of antibiotic treatments. Materials and methods: Information regarding wards, specimen types, species, and antibiotic resistance profile of 1994 strains of Pseudomonas spp. Isolated over a period of 6 years in Mures Clinical County Hospital, Romania, was collected from the WHONET database. From 50 multidrug-resistant isolates, molecular fingerprinting was performed by Enterobacterial Repetitive Intergenic Consensus Polymerase Chain Reaction (ERIC-PCR) to prove the potential clonal distribution. Results: A number of 1994 Pseudomonas spp. were isolated between 2017–2022, from which P. aeruginosa was the most frequent species, 97.39% (n = 1942). P. aeruginosa was most frequently isolated in 2017 (n = 538), with the dermatology department as the main source, mainly from pus secretion. A drop in the harvesting rate was noted in 2020 due to COVID-19 restrictions. Regarding the resistance profile, there are a few modifications. The susceptibility of P. aeruginosa to carbapenems, piperacillin-tazobactam, and amikacin suffered alterations before and during COVID-19. The molecular fingerprinting showed three P. aeruginosa clusters, including strains with 80–99% similarity.

show abstract

Section: Discussionmentioning

confidence: 99%

Epidemiology, Evolution of Antimicrobial Profile and Genomic Fingerprints of Pseudomonas aeruginosa before and during COVID-19: Transition from Resistance to Susceptibility

Coșeriu

Vintilă

Mare

et al. 2022

Life

View full text Add to dashboard Cite

show abstract

“…For all these reasons, it is striking that there have not been any large-scale clinical trials on the effect of bronchodilators in patients with bronchiectasis, a disease that is associated with more than 25% of COPD and severe asthma cases [20,21] and is, moreover, the third most frequent chronic inflammatory disease of the airway, after COPD and asthma [1]. May this editorial serve as a wake-up call for the scientific community to carry out these necessary clinical trials to confirm what physicians seem to have already decided: that long-acting bronchodilators, whether alone or in combination, are effective, at least in the improvement of some fundamental outcomes in patients with bronchiectasis and airflow obstruction such as exacerbations [22][23][24], and the impact of this treatment in some specific traits in bronchiectasis such as neutrophilic inflammation [25] or the microbiome [26][27][28]. Until this scientific evidence arrives, studies such as those by Shi et al are important for assessing which individuals with bronchiectasis are most suited for inclusion in an RCT.…”

mentioning

confidence: 87%

Bronchodilators in bronchiectasis: we urgently need more trials

Martínez‐García

2023

Lung

View full text Add to dashboard Cite

“…Airway bacterial load is a key component in the pathophysiology of CBI in patients with bronchiectasis [49] and other chronic inflammatory diseases [5,50]. It has been demonstrated that a high bacterial load is associated with increased local and systemic inflammation, more severe disease and poorer clinical outcomes.…”

Section: Microbiological Issuesmentioning

confidence: 99%

Efficacy and Safety of Dry Powder Antibiotics: A Narrative Review

Rosa

Suárez-Cuartín

Sibila

et al. 2023

JCM

View full text Add to dashboard Cite

The use of inhaled antibiotics was initially almost exclusively confined to patients with cystic fibrosis (CF). However, it has been extended in recent decades to patients with non-CF bronchiectasis or chronic obstructive pulmonary disease who present with chronic bronchial infection by potentially pathogenic microorganisms. Inhaled antibiotics reach high concentrations in the area of infection, which enhances their effect and enables their long-term administration to defeat the most resistant infections, while minimizing possible adverse effects. New formulations of inhaled dry powder antibiotics have been developed, providing, among other advantages, faster preparation and administration of the drug, as well as avoiding the requirement to clean nebulization equipment. In this review, we analyze the advantages and disadvantages of the different types of devices that allow the inhalation of antibiotics, especially dry powder inhalers. We describe their general characteristics, the different inhalers on the market and the proper way to use them. We analyze the factors that influence the way in which the dry powder drug reaches the lower airways, as well as aspects of microbiological effectiveness and risks of resistance development. We review the scientific evidence on the use of colistin and tobramycin with this type of device, both in patients with CF and with non-CF bronchiectasis. Finally, we discuss the literature on the development of new dry powder antibiotics.

show abstract

Pseudomonas aeruginosa Colonization and COPD: The Chicken or the Egg?

Cited by 10 publications

References 18 publications

Epidemiology, Evolution of Antimicrobial Profile and Genomic Fingerprints of Pseudomonas aeruginosa before and during COVID-19: Transition from Resistance to Susceptibility

Epidemiology, Evolution of Antimicrobial Profile and Genomic Fingerprints of Pseudomonas aeruginosa before and during COVID-19: Transition from Resistance to Susceptibility

Bronchodilators in bronchiectasis: we urgently need more trials

Efficacy and Safety of Dry Powder Antibiotics: A Narrative Review

Contact Info

Product

Resources

About